Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dashboard-driven individualized infliximab dosing versus standard dosing in acute severe ulcerative colitis
NL-OMON52704Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in autoimmune colitis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Treatment success at week 8. Started Sep 2019; status: terminated.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON52704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52704.